BNTX Quote, Financials, Valuation and Earnings

Moderna has a net margin of -227.46% compared to BioNTech SE's net margin of -907.48%. BioNTech SE's return on equity of -3.91% beat Moderna's return on equity of -29.23%.

BioNTech SE has a consensus price target of $136.58, signalling upside risk potential of 44.1%. On the other hand Moderna has an analysts' consensus of $46.96 which suggests that it could grow by 92.62%. Given that Moderna has higher upside potential than BioNTech SE, analysts believe Moderna is more attractive than BioNTech SE.

BioNTech SE has a beta of 1.347, which suggesting that the stock is 34.675% more volatile than S&P 500. In comparison Moderna has a beta of 1.995, suggesting its more volatile than the S&P 500 by 99.542%.

BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNTech SE pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

BioNTech SE quarterly revenues are $192.3M, which are larger than Moderna quarterly revenues of $107M. BioNTech SE's net income of -$437.5M is higher than Moderna's net income of -$971M. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 7.68x versus 3.02x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

NuCana PLC has a net margin of -227.46% compared to BioNTech SE's net margin of --. BioNTech SE's return on equity of -3.91% beat NuCana PLC's return on equity of --.

BioNTech SE has a consensus price target of $136.58, signalling upside risk potential of 44.1%. On the other hand NuCana PLC has an analysts' consensus of $104.00 which suggests that it could grow by 100969%. Given that NuCana PLC has higher upside potential than BioNTech SE, analysts believe NuCana PLC is more attractive than BioNTech SE.

BioNTech SE has a beta of 1.347, which suggesting that the stock is 34.675% more volatile than S&P 500. In comparison NuCana PLC has a beta of 1.639, suggesting its more volatile than the S&P 500 by 63.921%.

BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNTech SE pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.

BioNTech SE quarterly revenues are $192.3M, which are larger than NuCana PLC quarterly revenues of --. BioNTech SE's net income of -$437.5M is lower than NuCana PLC's net income of -$836.1K. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 7.68x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.

Novavax has a net margin of -227.46% compared to BioNTech SE's net margin of -91.76%. BioNTech SE's return on equity of -3.91% beat Novavax's return on equity of --.

BioNTech SE has a consensus price target of $136.58, signalling upside risk potential of 44.1%. On the other hand Novavax has an analysts' consensus of $15.57 which suggests that it could grow by 133.81%. Given that Novavax has higher upside potential than BioNTech SE, analysts believe Novavax is more attractive than BioNTech SE.

BioNTech SE has a beta of 1.347, which suggesting that the stock is 34.675% more volatile than S&P 500. In comparison Novavax has a beta of 3.210, suggesting its more volatile than the S&P 500 by 220.956%.

BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNTech SE pays -- of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend.

BioNTech SE quarterly revenues are $192.3M, which are larger than Novavax quarterly revenues of $88.3M. BioNTech SE's net income of -$437.5M is lower than Novavax's net income of -$81M. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while Novavax's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 7.68x versus 1.53x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.

Sanofi SA has a net margin of -227.46% compared to BioNTech SE's net margin of 17.65%. BioNTech SE's return on equity of -3.91% beat Sanofi SA's return on equity of 8.47%.

BioNTech SE has a consensus price target of $136.58, signalling upside risk potential of 44.1%. On the other hand Sanofi SA has an analysts' consensus of $64.64 which suggests that it could grow by 23.99%. Given that BioNTech SE has higher upside potential than Sanofi SA, analysts believe BioNTech SE is more attractive than Sanofi SA.

BioNTech SE has a beta of 1.347, which suggesting that the stock is 34.675% more volatile than S&P 500. In comparison Sanofi SA has a beta of 0.546, suggesting its less volatile than the S&P 500 by 45.374%.

BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sanofi SA offers a yield of 7.55% to investors and pays a quarterly dividend of $2.21 per share. BioNTech SE pays -- of its earnings as a dividend. Sanofi SA pays out 84.6% of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

BioNTech SE quarterly revenues are $192.3M, which are smaller than Sanofi SA quarterly revenues of $11.2B. BioNTech SE's net income of -$437.5M is lower than Sanofi SA's net income of $2B. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while Sanofi SA's PE ratio is 18.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 7.68x versus 2.68x for Sanofi SA. Usually stocks with elevated PS ratios are considered overvalued.